Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2006-05-30
2006-05-30
Guzo, David (Department: 1633)
Chemistry: molecular biology and microbiology
Vector, per se
C435S455000, C435S456000, C424S093100, C424S093200, C424S093600
Reexamination Certificate
active
07052904
ABSTRACT:
An adenovirus, including adenoviral capsid proteins, and a replication-defective adenoviral vector that includes a 5′ retroviral LTR nucleic acid sequence, a 3′ retroviral LTR nucleic acid sequence, a nucleic acid sequence encoding a portion of a retroviral envelope protein adjacent to either the 5′ LTR or the 3′ LTR nucleic acid sequence, a retroviral packaging sequence and a nucleic acid sequence encoding a transgene located between the 5′ LTR and the 3′ LTR is provided. Host cells infected with this adenovirus are also provided. An adenoviral vector is provided that includes an adenoviral polynucleotide sequence comprising a nucleic acid encoding a transgene, a retroviral packaging signal, a 5′ and a 3′ retroviral LTR, and a portion of a retroviral envelope polypeptide, wherein the adenoviral polynucleotide sequence does not encode one or more of E1, E3 or E4. A method for transforming a cell is also provided using a virus or a vector of the invention, as is a method for introducing a transgene into a cell that is not able to produce viral particles with a single viral vector. A method is also provided for preventing or treating disorder in a subject using the adenoviral vectors of the invention. A pharmaceutical composition is also provided that includes an adenoviral vector of the invention and a pharmaceutically acceptable carrier.
REFERENCES:
patent: 5585362 (1996-12-01), Wilson et al.
patent: 5948675 (1999-09-01), Klatzmann et al.
patent: 6001557 (1999-12-01), Wilson et al.
patent: 6303380 (2001-10-01), Lin et al.
patent: 6410011 (2002-06-01), Branellec et al.
patent: 2004/0248827 (2004-12-01), Zheng et al.
patent: WO 96/05321 (1996-02-01), None
patent: WO 97/25446 (1997-07-01), None
patent: WO 98/22143 (1998-05-01), None
patent: WO 99/32647 (1999-07-01), None
patent: WO 00/56910 (2000-09-01), None
patent: WO 02/061104 (2002-08-01), None
Dang, C.V. et al., “Gene Therapy and Translational Cancer Research”, 1999, Clinical Cancer Research, vol. 5: pp. 471-474.
Basak, S.K. et al. “Modifying Adenoviral Vectors for Use as Gene-Based Cancer Vaccines”, 2004, Viral Immunology, vol. 17: pp. 182-196.
Ratner, L., et al. “Complete nucleotide sequence of the AIDS virus, HTLV-III”, 1985, Nature, vol. 313: pp. 277-284.
Bilbao et al., “Adenoviral/Retroviral Vector Chimeras: A Novel Strategy to Achieve High-Efficiency Stable Transduction in vivo,”FASEB Journal11(8):624-634, Jul. 1997.
Zheng et al., “Genomic Integration and Gene Expression by a Modified Adenoviral Vector,”Nature Biotechnology18(2):176-180, Feb. 2000.
Caplen et al., “Adeno-retroviral chimeric viruses as in vivo transducing agents,”Gene Therapy6:454-459, 1999.
Duisit et al., “Functional characterization of adenoviral/retroviral chimeric vectors and their use for efficient screening of retroviral producer cell lines,”Hum. Gene Therap.10:189-200, 1999.
Feng et al., “Stable in vivo gene transduction via a novel adenoviral/retroviral cheric vector,”Nature Biotech. 15:886-870, 1997.
Lin, Construction of new retroviral producer cells from adenoviral and retroviral vectors,Gene Therap. 5:1251-1258, 1998.
Link, “Adenoviral vectors go retro,”Nature Biotech. 18: 150-157, 2000.
Robbins et al., “Viral vectors for gene therapy,”Pharmacol. Ther. 80:35-47, 1998.
Baum Bruce J.
O'Connell Brian
Zheng Changyu
Burkhart Michael D.
Guzo David
Klarquist & Sparkman, LLP
The United States of America as represented by the Secretary of
LandOfFree
Hybrid adeno-retroviral vector for the transfection of cells does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hybrid adeno-retroviral vector for the transfection of cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hybrid adeno-retroviral vector for the transfection of cells will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3526834